TP53 and neoplasm: The first-in-human trial of CX-5461 in patients with advanced haematological cancers (Peter MacCallum Cancer Centre) has demonstrated single-agent anti-tumour activity in TP53 wild type and TP53-mutant haematologic malignancies16.